BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Get in Touch
Interested in this coverage?
Reach out with questions or to discuss what you're tracking.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Cormorant Asset Management, LP Bright Minds Biosciences Pty Ltd (DRUG) | 9.2% -0.5 13G/A [SEC] |
EcoR1 Capital MEREO BIOPHARMA GROUP PL-ADR (MREO) | 6.0% -2.4 13G/A [SEC] |
Cormorant Asset Management, LP Rapport Therapeutics Inc. (RAPP) | 5.6% -0.6 13G/A [SEC] |
Cormorant Asset Management, LP BIOAGE LABS INC (BIOA) | 5.4% -1.1 13G/A [SEC] |
Cormorant Asset Management, LP CABALETTA BIO INC (CABA) | 6.0% -3.1 13G/A [SEC] |
Cormorant Asset Management, LP Rallybio Corp (RLYB) | 0.0% 13G/A [SEC] |
Cormorant Asset Management, LP | 8.3% 13G/A [SEC] |
Cormorant Asset Management, LP MoonLake Immunotherapeutics (MLTX) | 4.3% -1.9 13G/A [SEC] |
Perceptive Advisors X4 Pharmaceuticals, Inc (XFOR) | 8.1% +0.8 13G/A [SEC] |
BVF Partners L.P. Palvella Therapeutics, Inc. (PVLA) | 4.7% -2.4 13G/A [SEC] |
RA Capital Management GH RESEARCH PLC (GHRS) | 7.1% -5.3 13G/A [SEC] |
Perceptive Advisors NAUTILUS BIOTECHNOLOGY INC (NAUT) | 9.1% -1.0 13D/A [SEC] |
RA Capital Management Edgewise Therapeutics, Inc. (EWTX) | 7.8% -2.1 13G/A [SEC] |
Baker Brothers Advisors Edgewise Therapeutics, Inc. (EWTX) | 3.4% -3.5 13G/A [SEC] |
RA Capital Management Karyopharm Therapeutics Inc. (KPTI) | 9.9% 13G/A [SEC] |
| 58 more filings. View them all on the RxDataLab platform | |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
Perceptive Advisors KIORA PHARMACEUTICALS INC (KPRX) | 10.0% SC 13G [SEC] |
ARCH Venture Partners Parabilis Medicines, Inc. (PBLS) | 5.3% SC 13G [SEC] |
Baker Brothers Advisors Revolution Medicines, Inc. (RVMD) | 5.3% SC 13G [SEC] |
OrbiMed | 5.3% SC 13G [SEC] |
Baker Brothers Advisors IDEAYA Biosciences, Inc. (IDYA) | 5.2% SC 13G [SEC] |
OrbiMed Lexeo Therapeutics (LXEO) | 4.1% SC 13G [SEC] |
Multi-Fund Activity
Companies with filings from multiple institutional investors this week.
| Company | Funds | Net Change |
|---|---|---|
| Rapport Therapeutics Inc. (RAPP) | 2 | -7.0% |
| Avalo Therapeutics, Inc. (AVTX) | 2 | -8.3% |
| Edgewise Therapeutics, Inc. (EWTX) | 2 | -5.6% |
| SAB BIOTHERAPEUTICS INC (SABS) | 2 | -1.1% |
| TENAX THERAPEUTICS, INC. (TENX) | 2 | -1.0% |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.